Danoprevir Demonstrated an 85% Sustained Virologic Response Rate
Share
Follow Us
New hepatitis C drug shows potential in phase 2 trials
The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin.
“Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events,” said Patrick Marcellin, lead study author from the Service d’Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. “The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease.”
Continue reading this entire article:
http://www.thealmagest.com/new-hepatitis-c-drug-shows-potential-phase-2-trials/7267
